Liquidia (LQDA) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed Liquidia (LQDA) over the past year, gaining 235.8% versus a gain of 16.4%. MBX Biosciences is the larger company by market cap ($2.56 billion vs $2.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | MBX |
|---|---|---|
| Share price | $28.02 | $53.25 |
| Market cap | $2.51B | $2.56B |
| 1-day change | +5.02% | -2.37% |
| YTD return | -18.76% | +68.83% |
| 1-year return | +16.36% | +235.75% |
| 5-year return | +775.63% | — |
| P/E ratio (TTM) | 20.16 | — |
| Forward P/E | 11.66 | — |
| EPS (TTM) | $1.39 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $158.32M | — |
| Revenue growth (YoY) | +1031.18% | — |
| Net income (latest FY) | $-68.92M | $-87.00M |
| Operating margin | -32.45% | — |
| Net margin | -43.53% | — |
| 52-week high | $93.61 | $72.64 |
| 52-week low | $21.94 | $12.94 |
| Distance from 52-week high | -70.07% | -26.69% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +77.27% | +77.09% |
| Average volume | 2.40M | 539.34K |
| Shares outstanding | 89.51M | 48.16M |
| Employees | 216 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed LQDA by 219.4 percentage points over the past year.
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
LQDA vs MBX FAQ
Which is bigger, Liquidia or MBX Biosciences?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.56B compared with $2.51B for Liquidia (LQDA).
Which stock has performed better over the past year, LQDA or MBX?
MBX returned +235.75% over the past 12 months, compared with +16.36% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.